pharmaphorum5d
Lilly's Alzheimer's drug Kisunla is cleared in China
China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...
Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has ...
BioSpace21h
2024 Highlights the Rollercoaster That Is Neuro
This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and ...
EconoTimes5d
Eli Lilly’s Kisunla Approved in China, Paving the Way for Innovative Alzheimer’s Treatment Options
China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...
Morningstar6d
Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024 "Bringing Alzheimer's disease treatment options to ...
China Approves Lilly's Kisunla For Early Symptomatic Alzheimer's Disease Treatment
Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt, ...
Eli Lilly's Alzheimer's treatment approved in China
China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...
FOX 9 Minneapolis-St. Paul on MSN5d
Minnesotans battling Alzheimer's Disease now getting promising new treatment
FOX 9 caught up with a Minnesota woman undergoing a new Alzheimer’s treatment which is showing promise in slowing cognitive ...